KAM
VNDA icon

Krensavage Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Krensavage Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.16M Hold
1,180,388
– – 3.19% 10
2025
Q4 		$10.4M Hold
1,180,388
– – 3.68% 11
2025
Q3 		$5.89M Buy
1,180,388
+155,505
+15% +$720K 2.51% 14
2025
Q2 		$4.84M Buy
1,024,883
+270,502
+36% +$1.18M 2.56% 14
2025
Q1 		$3.46M Buy
754,381
+375,619
+99% +$1.75M 1.91% 13
2024
Q4 		$1.81M Sell
378,762
-35,922
-9% -$172K 1.07% 11
2024
Q3 		$1.95M Sell
414,684
-247,482
-37% -$1.33M 1.09% 11
2024
Q2 		$3.74M Buy
+662,166
New +$3.42M 1.72% 12
2023
Q4 		– Sell
-360,429
Closed -$1.56M – 15
2023
Q3 		$1.56M Sell
360,429
-2,522
-0.7% -$14K 0.57% 11
2023
Q2 		$2.39M Buy
362,951
+1,391
+0.4% +$8.92K 0.76% 10
2023
Q1 		$2.46M Buy
361,560
+16,270
+5% +$114K 0.75% 12
2022
Q4 		$2.55M Buy
345,290
+32,991
+11% +$321K 0.79% 12
2022
Q3 		$3.09M Buy
+312,299
New +$3.3M 0.98% 13

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Krensavage Asset Management's VNDA Position: Q1 2026 in Review

Krensavage Asset Management held its Vanda Pharmaceuticals (VNDA) position steady in Q1 2026 at 1,180,388 shares worth $8.16M. The position accounts for 3.19% of the portfolio, ranked #10.

Krensavage Asset Management first reported a position in VNDA in Q3 2022 and has held it in 13 quarters since. The position peaked at $10.4M in Q4 2025. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Krensavage Asset Management held 1,180,388 shares of Vanda Pharmaceuticals worth $8.16M as of Q1 2026.
  • Krensavage Asset Management left its Vanda Pharmaceuticals share count unchanged in Q1 2026.
  • Vanda Pharmaceuticals made up 3.19% of Krensavage Asset Management's portfolio in Q1 2026, its #10 holding.
  • Krensavage Asset Management first reported a position in Vanda Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Krensavage Asset Management's Vanda Pharmaceuticals position peaked at $10.4M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.